On the stock market since 2012, it operates in the world of health and science. It has 10 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $21.0M in the vault; even if every debt were paid off, $21.0M would remain.
A loss of $8.7M against $0 in annual sales.
The stock sits at $0.02. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 2.4 years. After that, the company needs to find new money.
On our five-subject report card, PHIOW sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PHIOW is a high-risk stock — not yet profitable, and its future rides on its product catching on.